Product Images Aripiprazole

This is a description of a prescription medication called Aripiprazole Tablets, USP. Each tablet contains 10 mg of Aripiprazole. It is manufactured by Ascent Pharmaceuticals, Inc. and is used according to the package insert's full prescribing information. It is to be stored at 20° to 25°C (68° to 77°F) in tightly closed containers. This medication is distributed by XLCare Pharmaceuticals, Inc. located at 242 South Culver Street, Suite 202, Lawrenceville, GA 30046.*

XLcare Pharmaceuticals, Inc. provides Aripiprazole Tablets, USP in a pack of 500 tablets. Each tablet contains 15 mg of Aripiprazole USP. The pharmacist must dispense a medical guide separately to each patient. The package insert must be referred to by the patient for full prescribing information. The tablets should be stored in tightly closed containers at controlled room temperature. The manufacturing was done by Ascent Pharmaceuticals, Inc. located in Central Islip, NY 11722. The last revision was in November 2020.*

XLcare Pharmaceuticals Inc. produces Aripiprazole tablets. Each tablet contains 2mg of Aripiprazole USP, and the usual dosage can be found in the package insert. Store tablets in tightly closed containers at 20°C to 25°C. The manufacturers are Ascent Pharmaceuticals, Inc. and XLCare Pharmaceuticals, Inc., located in Central Islip, NY, and Lawrenceville, GA, respectively. This medication is only available by prescription.*

XLcare Pharmaceuticals is a company that produces Aripiprazole tablets, which are only available by prescription. Each tablet contains 20 mg of aripiprazole USP, and the usual dosage should be consulted from the package insert for full prescribing information. It is recommended to store the tablets in tightly closed containers at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. The tablets come in a pack of 500 and the manufacturing is done by Ascent Pharmaceuticals, Inc. in Central Islip, NY 11722. Pharmacist DPense e Medcalon Gude is provided separately in each package.*

XLcare Pharmaceuticals, Inc. provides Aripiprazole tablets, USP in a container with 500 tablets. Each tablet consists of 30 mg of Aripiprazole USP, and the usual dosage should be checked from the package insert. The pharmacist has to dispense the medicine, and the medical guide is provided separately with each patient. Store these tablets in a tightly closed container between 20°C to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. These tablets are manufactured by Ascent Pharmaceuticals, Inc. in Central Islip, NY 11722, for XLCare Pharmaceuticals, Inc. The document revision date is 11/20.*

This is a description of a medication called Aripiprazole. It comes in tablet form with each tablet containing 5mg of the medication. The typical dosage instructions are included in the package insert. The manufacturer of the medication is XLCare Pharmaceuticals and it is made by Ascent Pharmaceuticals. It should be stored in tightly closed containers at room temperature. A pharmacist guide is provided to each patient.*

This is a chart showing the effect of different drugs on the pharmacokinetics of aripiprazole, presented as fold change and 90%. It includes information on drugs that inhibit or induce certain enzymes involved in aripiprazole metabolism, as well as gastric acid blockers. The chart includes numerical values and a graph depicting the relative change compared to a reference without interacting drugs.*

This appears to be a table or chart showing the effect of various drugs on the drug Aripiprazole. The drugs listed include Ketoconazole, CYe2Ds, Oaindine, Catamazapine, Amotdine, Vit, Tio, and Orazspam. The chart also shows a percentage of change in relation to a reference point (with no interacting drug) at various intervals of 5. There is not enough context to determine the exact meaning of these numbers or the purpose of the chart.*

This is a table of different special populations and factors that may affect their pharmacokinetics, including CYP2D6 metabolism, gender, age, and hepatic or renal impairment. The table also shows different pharmacokinetic parameters that were measured such as AUC and Cmax. The table concludes with a graphical representation of fold change and 90% confidence interval for Ariprprazole relative to reference in different change values.*

This appears to be a graph depicting the proportion of subjects experiencing a relapse over time (in days) during a study comparing the drug "Arpiprazole" to a placebo. The X-axis shows the number of days from randomization and the Y-axis shows the proportion of subjects. The drug and placebo groups are depicted with different colored lines. The graph suggests that Arpiprazole may be more effective than placebo in preventing relapses over time, as the proportion of relapses in the drug group appears to be consistently lower than in the placebo group.*